Publications
- Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed2017 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib2016 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Science
- Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy2016 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib2016 | Faculty of Medicine in Pilsen, Faculty of Science
- High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib2015 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Science
- The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study2015 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib2014 | Faculty of Medicine in Pilsen
- Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?2024 | Faculty of Medicine in Pilsen
- Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate2024 | Faculty of Medicine in Pilsen
- Pembrolizumab plus enfortumab vedotin in urothelial cancer2024 | Faculty of Medicine in Pilsen
Loading network view...